Actinium Pharmaceuticals (ATNM) Competitors $1.58 -0.02 (-1.25%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.60 +0.02 (+1.27%) As of 06:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ATNM vs. ACTU, DSGN, ENGN, KOD, TNXP, CRDF, SOPH, VYGR, YMAB, and CRGXShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Actuate Therapeutics (ACTU), Design Therapeutics (DSGN), enGene (ENGN), Kodiak Sciences (KOD), Tonix Pharmaceuticals (TNXP), Cardiff Oncology (CRDF), SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Actuate Therapeutics Design Therapeutics enGene Kodiak Sciences Tonix Pharmaceuticals Cardiff Oncology SOPHiA GENETICS Voyager Therapeutics Y-mAbs Therapeutics CARGO Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Which has higher earnings and valuation, ACTU or ATNM? Actuate Therapeutics has higher earnings, but lower revenue than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/AActinium Pharmaceuticals$81K608.51-$48.82M-$1.39-1.14 Do analysts prefer ACTU or ATNM? Actuate Therapeutics currently has a consensus target price of $20.50, suggesting a potential upside of 93.95%. Actinium Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 153.16%. Given Actinium Pharmaceuticals' higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to ACTU or ATNM? In the previous week, Actinium Pharmaceuticals had 8 more articles in the media than Actuate Therapeutics. MarketBeat recorded 9 mentions for Actinium Pharmaceuticals and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.40 beat Actinium Pharmaceuticals' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Actuate Therapeutics Positive Actinium Pharmaceuticals Neutral Does the MarketBeat Community believe in ACTU or ATNM? Actinium Pharmaceuticals received 9 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 47.83% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformActuate TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesActinium PharmaceuticalsOutperform Votes1147.83% Underperform Votes1252.17% Is ACTU or ATNM more profitable? Actuate Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Actinium Pharmaceuticals N/A -100.85%-47.89% Do insiders & institutionals have more ownership in ACTU or ATNM? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryActuate Therapeutics beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$49.29M$6.53B$5.38B$19.45BDividend YieldN/A2.64%5.28%3.91%P/E Ratio-1.148.7326.9934.73Price / Sales608.51257.87412.1741.78Price / CashN/A65.8538.2517.51Price / Book1.216.466.844.74Net Income-$48.82M$143.21M$3.22B$1.02B7 Day Performance-3.66%4.49%2.48%1.52%1 Month Performance3.95%2.61%9.71%5.32%1 Year PerformanceN/A0.65%20.96%6.34% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.539 of 5 stars$1.58-1.3%$4.00+153.2%N/A$49.29M$81,000.00-1.1430ACTUActuate TherapeuticsN/A$10.26-2.7%$20.50+99.8%N/A$206.06MN/A0.0010Positive NewsDSGNDesign Therapeutics0.4153 of 5 stars$3.53+0.6%$4.00+13.3%+4.2%$200.40MN/A-4.1540ENGNenGene3.1663 of 5 stars$3.91+13.3%$23.29+495.5%-68.0%$199.32MN/A-6.7431Short Interest ↓KODKodiak Sciences4.1354 of 5 stars$3.71+6.0%$9.00+142.6%+21.0%$195.75MN/A-1.0290Gap DownTNXPTonix Pharmaceuticals3.7196 of 5 stars$26.60-5.0%$585.00+2,099.2%-92.4%$194.85M$10.04M-0.0150Analyst RevisionHigh Trading VolumeCRDFCardiff Oncology1.789 of 5 stars$2.91+3.6%$12.00+312.4%+4.4%$193.59M$587,000.00-3.1020Positive NewsSOPHSOPHiA GENETICS2.6701 of 5 stars$2.86-3.4%$6.80+137.8%-44.2%$190.73M$67.17M-2.62520Short Interest ↓VYGRVoyager Therapeutics4.6416 of 5 stars$3.43+3.9%$13.39+290.4%-63.9%$189.80M$66.96M4.83100YMABY-mAbs Therapeutics3.7598 of 5 stars$4.17+1.7%$16.60+298.1%-61.3%$188.83M$87.69M-7.72150Analyst ForecastCRGXCARGO Therapeutics2.315 of 5 stars$4.09-0.7%$15.00+266.7%-76.6%$188.59MN/A-0.96116Positive News Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Design Therapeutics Alternatives enGene Alternatives Kodiak Sciences Alternatives Tonix Pharmaceuticals Alternatives Cardiff Oncology Alternatives SOPHiA GENETICS Alternatives Voyager Therapeutics Alternatives Y-mAbs Therapeutics Alternatives CARGO Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored"I'm risking my reputation on this"The Secret Behind 90% of Crypto’s Biggest Gains There are plenty solution-driven opportunities emerging rig...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNM Stock Free ATNM Stock Alerts